
Sign up to save your podcasts
Or


Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831
By BMJ Group4.2
99 ratings
Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831

501 Listeners

38 Listeners

47 Listeners

298 Listeners

4 Listeners

9 Listeners

6 Listeners

3 Listeners

2 Listeners

3 Listeners

26 Listeners

41 Listeners

14 Listeners

1 Listeners

55 Listeners

0 Listeners

6 Listeners

15 Listeners

3 Listeners

26 Listeners

23 Listeners

135 Listeners

1,286 Listeners

81 Listeners

0 Listeners